Food and Drug Administration

High-frequency Electrical Stimulation Helps Reduce Inflammation, Pain in New Feinstein Institutes Study

Retrieved on: 
Wednesday, October 5, 2022
Health, Medical Devices, Neurology, Clinical Trials, Research, Science, Biotechnology, Quality of life, LinkedIn, Suicide, Yang, HMGB1, Nociceptor, Observation, Medicine, Optogenetics, Science, Medical research, Proceedings of the National Academy of Sciences of the United States of America, Depression, Research, Electrode, PNAS, Multimedia, Feinstein Institute for Medical Research, Inflammation, Mental health, Institute, Technology, Cancer, Food, Neuron, Molecular medicine, Substance P, Food and Drug Administration, Doctor of Philosophy, DRS, CEO, Pain, HFES, Neuroinflammation, Autoimmunity, Overalls, Skin, Genetics, Anxiety, Chronic pain, Northwell Health, National academy, CGRP, Poultry, Medical device, Dentistry, MD

And while pain is an important defense mechanism to protect the body and promote healing, chronic pain can be debilitating.

Key Points: 
  • And while pain is an important defense mechanism to protect the body and promote healing, chronic pain can be debilitating.
  • The research, led by Feinstein Institutes Sangeeta Chavan, PhD , showed in preclinical mice models that HFES inhibits neuroinflammatory mediator release by sensory neurons, called nociceptors, to reduce pain.
  • For your body to feel pain, neurons release molecules that kickstart the bodys immune response causing inflammation and pain.
  • We now have a better understanding as to why high-frequency stimulation helps attenuate inflammation and associated pain.

Regenerative Medicine Market to Reach US$ 85.3 Bn by the year 2032 Owing to its Wide Acceptance in the Healthcare Industry - Future Market Insights, Inc.

Retrieved on: 
Wednesday, October 5, 2022
Adoption, Prevalence, Growth, Population, Ophthalmology, EMA, Cardiology, Food and Drug Administration, Degenerative disease, CAGR, Gene editing, Research, Technology, Food, Industry, Health, European Medicines Agency, Conditional sentence, Injury, EC, Regenerative medicine, Ageing, PSC, Projection, FDA, Solution, Medical device, Pharmaceutical industry

NEWARK, Del., Oct. 5, 2022 /PRNewswire/ -- The global regenerative medicine market is anticipated to register a phenomenal growth of 23.9% with an evaluation of around US$ 9.9 Bn by the end of the year 2022 and is further expected to enjoy an estimation of US$ 85.3 Bn by the year 2032.

Key Points: 
  • Demand for regenerative medicine in Europe is expected to grow at a CAGR of 24.7% of the global regenerative medicine market.
  • South Asia region is expected to grow with a CAGR of 30.8% in the global regenerative medicine market.
  • The targeted therapeutic market is expected to generate a revenue of around US$ 100.9 Bn by contributing about 8.3% to the global regenerative medicine market.
  • An opportunistic outlook is presented by the regenerative medicine market in the future owing to the beneficial outcomes of regenerative medicine.

Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
IOV, SAN, TIL, U.S. Securities and Exchange Commission, Risk, PSLRA, Webcast, Life, Investor, TALEN, SITC, Annual report, NASDAQ, ICI, Patient, Perception, Security (finance), Annual general meeting, Immunotherapy, Time, Cancer, Private Securities Litigation Reform Act, Food, NSCLC, Food and Drug Administration, Concurrency, Society, Cervical cancer, BLA, Safety, GLOBE, Clinical trial, Forward-looking statement, FDA, COVID-19, Poster, Pharmaceutical industry, Iovance Biotherapeutics

ET to discuss the pooled analysis of Cohorts 2 and 4 of the C-144-01 study of lifileucel in advanced melanoma.

Key Points: 
  • ET to discuss the pooled analysis of Cohorts 2 and 4 of the C-144-01 study of lifileucel in advanced melanoma.
  • The live and archived webcast will be available in the Investors section of the companys website at www.iovance.com .
  • Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
  • Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer.

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Pembrolizumab, Regulatory T cell, Drug Quality and Security Act, Head, Science, SITC, Policy, Annual report, Securities Exchange Act of 1934, Patient, H. Lee Moffitt Cancer Center & Research Institute, Result, Research, Financial condition report, Immunotherapy, Nasdaq, Securities Act of 1933, Cancer, Conversation, Society for Immunotherapy of Cancer, Food, PMHC cellular microarray, Hall, Food and Drug Administration, Department, Analysis, Society, Board, HPV16, Patent, Selective, GLOBE, EST, IL-2, Board of directors, Forward-looking statement, FDA, COVID-19, Form 10-Q, Risk, Pharmaceutical industry, Vaccine, Animal

EST

Key Points: 
  • EST
    Date: Friday, November 11, 2022, Poster Hall (Hall C) 9 a.m.8:30 p.m. EST
    Date: Thursday, November 10, 2022, Poster Hall (Hall C) 9a.m.9p.m.
  • EST
    All posters will be available to conference attendees as virtual e-posters during SITC 2022.
  • The posters will also be available on November 10, 2022 in the Investor & Media section of the Companys website at www.cuebiopharma.com , underScientific Publicationsand Presentations.
  • The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules.

Second Annual RARE Health Equity Summit Addresses Gaps in Access, Shares Approaches to Build Inclusiveness in Underserved Communities

Retrieved on: 
Wednesday, October 5, 2022
Medical Devices, General Health, Professional Services, Public Policy, Government, Genetics, DEI (Diversity, Equity and Inclusion), Clinical Trials, FDA, Media, Biotechnology, Health, White House, Federal Government, Communications, Social Services, Social Activism, Pharmaceutical, Oncology, Doctor of Pharmacy, Caregiver, Color, Global Genes, Movement, Master of Philosophy, Disease, Technology, JD, Senior lecturer, MS, Hope, Dentistry, Diagnosis, Gaps, University of Science and Technology, Diversity, University of Aberdeen School of Medicine and Dentistry, Patient, Bias, Health equity, MBA, Love, MPH, Partnership, History, Degenerative disease, Commissioner, Solution, Food and Drug Administration, Industry, Health, DO, Rare disease, National Center for Advancing Translational Sciences, CEO, FTSE Global Equity Index Series, Summit, Treatment, Genetic testing, Interim, Environment, Coalition, National Center for Civil and Human Rights, Artifact, FDA, School, National Institute on Minority Health and Health Disparities, Medical device, Vaccine, MD

Global Genes , a leading rare disease advocacy organization, will hold its second annual RARE Health Equity Summit in partnership with the Rare Disease Diversity Coalition (RDDC).

Key Points: 
  • Global Genes , a leading rare disease advocacy organization, will hold its second annual RARE Health Equity Summit in partnership with the Rare Disease Diversity Coalition (RDDC).
  • The event includes speakers from the FDA, community and patient organizations, academia and industry and will discuss approaches to address racial, ethnic, gender, socioeconomic and other disparities affecting rare disease communities.
  • The takeaways from last years inaugural Health Equity Summit highlighted the work that we must do as a community to break down barriers.
  • Black Womens Health Imperative (BWHI) launched the Rare Disease Diversity Coalition (RDDC) to address the extraordinary challenges faced by rare disease patients of color.

Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy

Retrieved on: 
Wednesday, October 5, 2022
News, Therapy, Chronic kidney disease, ISN, IND, IgA nephropathy, China Media Group Headquarters, ICB, HKEX, Patient, Social conditioning, Research, Thrombotic microangiopathy, Inflammation, Process, Food, MASP2, Discovery, Food and Drug Administration, Mab, Nature, TMA, Immunoglobulin A, Environment, Time-invariant system, Headquarters, FDA, Suzhou Industrial Park, Fine chemical, Vaccine, Pharmaceutical industry

Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.

Key Points: 
  • Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
  • TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation.
  • TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the lectin pathway complement-mediated inflammation.
  • Transcenta discovered and developed TST004 in-house and plan to develop TST004 for IgA nephropathy (IgAN), a highly prevalent chronic kidney disease with very limited treatment options.

CBD Move Free Partners with Arbor Hemp to Launch New Clinically Studied Products Designed to Improve Sleep and Aid with Weight Loss Goals

Retrieved on: 
Tuesday, October 4, 2022
Time, Cannabis, Weight loss, Disease, Appetite, BMI, Life, REM, THCV, Education, Food and Drug Administration, Tree, Slim, Varin, JPS, Carbon, Endocannabinoid system, Multimedia, Empowerment, Partnership, Rest, Food, Industry, CEO, Pain, Bacteria, Environment, Anxiety, Mood, Pharmaceutical industry, Dietary supplement, CBD, Sleep, Hemp

BELLEVUE, Wash., Oct. 4, 2022 /PRNewswire/ -- CBD Move Free, a line of unique CBD relief products designed to maximize everyday life, is today announcing a collaboration with Arbor Hemp, a hemp company offering clinically studied plant-sourced solutions. The partnership will initially result in the launch of two co-branded products, Sleep Soft Gels and Slim Soft Gels, which are geared towards those looking to improve sleep and curb cravings with natural, clinically studied, hemp extract supplements they can trust. The two new products add to CBD Move Free's robust line of products that focus on rest and recovery.

Key Points: 
  • The two new products add to CBD Move Free's robust line of products that focus on rest and recovery.
  • Participants taking active doses of the Sleep product saw major improvements in sleep, especially deep sleep known as REM.
  • Each box of CBD Move Free Arbor Sleep and CBD Move Free Arbor Slim provides 30 soft gels developed with 1000mg of Hemp extract.
  • CBD Move Free is the dba of JPS Products, Inc. JPS Products, Inc. also operates the brands Hemp Move Free and JPS Move Free.

Centinel Spine® Continues Launch of New Portfolio of prodisc® Cervical Total Disc Replacement Devices & Features at NASS 2022

Retrieved on: 
Tuesday, October 4, 2022
Solution, NASS, CORE, Samuel Bryan, Annual general meeting, Culture, Technology, Industry, Food, FDA, TDR, Anatomy, Food and Drug Administration, Pathology, North American Spine Society, LLC, WEST, Disarticulation, Spine, Surgeon, Bookbinding, Medical device

Centinel Spine now has four FDA-approved cervical total disc replacement devices for 1-level indications, offering the broadest spectrum of solutions to address surgeon preference and individual patient anatomy.

Key Points: 
  • Centinel Spine now has four FDA-approved cervical total disc replacement devices for 1-level indications, offering the broadest spectrum of solutions to address surgeon preference and individual patient anatomy.
  • WEST CHESTER, Pa., Oct. 4, 2022 /PRNewswire/ -- Centinel Spine, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced continued expansion of the availability of the prodisc Cervical Total Disc Replacement (TDR) portfolio that allows the disc to be matched to patient anatomy.
  • In July, the company received U.S. Food and Drug Administration approval for 1-level indications for prodisc C Vivo, prodisc C SK, and prodisc C Nova.
  • The new prodisc portfolio of cervical and lumbar TDR products will be featured at the Centinel Spine booth #4224, as well as multiple podium presentations during NASS 2022.

Medical Marijuana, Inc. Enters Into Asset Purchase Agreement With MFINITY Global LLC; Appoints MFINITY President as Kannaway President

Retrieved on: 
Tuesday, October 4, 2022
Safe harbor, The O.C., GLOBE, OTC, Securities Exchange Act of 1934, Medical cannabis, DRUG, Disease, Nature, Drug Quality and Security Act, Food, Medical Marijuana, Inc., CBD, CEO, Vitis rotundifolia, FDA, Growth, CA, Brand, LLC, Safety, CNBC, SAN, Sale, Acquisition, Food and Drug Administration, Securities Act of 1933, Company, Drug, Risk management

Additionally, Bill Andreoli, the President of MFINITY Global will become the President of Medical Marijuana, Inc. subsidiary, Kannaway, LLC.

Key Points: 
  • Additionally, Bill Andreoli, the President of MFINITY Global will become the President of Medical Marijuana, Inc. subsidiary, Kannaway, LLC.
  • MFINITY products will be marketed and sold exclusively under the Kannaway brand and are now available for sale through Kannaway independent distributors and on Kannaway.com.
  • The asset purchase aligns with Medical Marijuana Inc.s newly implemented growth model of expansion via acquisition.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, October 4, 2022
Securities Exchange Act of 1934, Court, News, Labour government, United, The Legal 500, Company, FDA, Death, Bacteria, Laboratory, Food and Drug Administration, Safety, District court, NYSE, Similac, Cronobacter sakazakii, Investment, NEW, Infant, Advertising, GLOBE, Fine chemical, Online gambling, Medical device, Abbott Laboratories, Cronobacter

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.